Clinical Profile and Outcome of Patients with Stage I–III Breast Cancer Treated at the Regional Cancer Centre, Thiruvananthapuram

Aim. To summarize the results of 19-year activity in laboratory of immunohistochemical tumor diagnosis of Tatarstan Regional Cancer Centre of Ministry of Health, Republic of Tatarstan.Methods. Advantages and limitations of modern molecular techniques for the diagnosis of human tumors are discussed based on our own experience and the literature data.Results. A number of tumor cells molecular targets (e.g., growth factor receptors, differentiation antigens) are being determined in Tatarstan Regional Cancer Centre since 1996 on the daily basis for creating a «molecular portrait of tumor» and customized therapy adjustment. The total number of tumors investigated using immunohistochemistry, systematically increased from 150 in 1996 to 5910 in 2014, and for each tumor 1 to 12 (usually 4-5) or more antigens expression is evaluated. Since 2007, molecular cytogenetic studies of potential targets for the treatment of breast cancer, stomach and lung are investigated. To identify HER2 oncogene amplification performed 894 assays were performed in 2007-2011 using chromogenic in situ hybridization and 1064 assays using fluorescence in situ hybridization were performed in 2011-2014. Since November 2014 we are using fluorescence in situ hybridization to detect ALK-EML4 translocation in lung adenocarcinomas, during the last month of the 2014 38 tests were performed. For two decades, the laboratory, which has a reference status in the Volga region of Russian Federation, has verified the diagnosis in 32 thousand patients, among them 55% cases of breast cancer (prognostic markers), 18% - lymphoproliferative processes, 15% - anaplastic tumors and metastatic cancers of unknown primary source, 12% were soft tissue tumors. Error rate for immunohistochemical diagnosis was 2.6%, mainly involving central nervous system tumors, lymphomas, and metastatic cancers of unknown primary source.Conclusion. Modern morphological tumor verification provides high quality diagnosis and treatment of cancer patients in the Republic of Tatarstan for many years.

Download Full-text

Triple Negative Breast Cancer in People of North East India: Critical Insights Gained at a Regional Cancer Centre

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2014.15.11.4507 ◽

2014 ◽

Vol 15 (11) ◽

pp. 4507-4511 ◽

Cited By ~ 17

Author(s):

Mousumi Sharma ◽

Jagannath Dev Sharma ◽

Anupam Sarma ◽

Shiraj Ahmed1 ◽

Amal Chandra Kataki ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Cancer Centre ◽

North East India ◽

North East ◽

Regional Cancer Centre

Download Full-text

Breast cancer wait times: Use of breast screening clinics affect presenting stage

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.10686 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 10686-10686

Author(s):

J. Hodgins ◽

C. Hamm

Keyword(s):

Breast Cancer ◽

Breast Screening ◽

Direct Access ◽

Wait Times ◽

Breast Cancer Patients ◽

Cancer Centre ◽

Number Of Patients ◽

Diagnostic Biopsy ◽

Definitive Surgery ◽

Regional Cancer Centre

10686 Background: Wait times in the navigation of the diagnostic and therapeutic system of breast cancer have been increasingly investigated. It is inherently apparent that an earlier diagnosis would lead to an improved prognosis in breast cancer. In Ontario (Canada) Breast Screening Clinics (OBSC) allow direct access of patients to mammograms. Methods: A retrospective review of all breast cancer patients seen in the regional cancer centre in the year 2003 was performed. Wait times between the following events were recorded: first symptom to presentation to medical system, presentation to mammogram, mammogram to biopsy, biopsy to surgery, surgery to consultation at cancer centre. Results: In 2003, 277 new cases of breast cancer were seen at the regional cancer centre. Identified median waiting times were as follows: mammogram to diagnostic biopsy - 18.5 days, diagnostic biopsy to definitive surgery - 28 days; surgical consultation to definitive surgery - 13 days; definitive surgery to oncology consultation - 31 days. Some wait times were longer in those patients who did not have close geographic access to OBSC and a regional cancer centre: mammography to diagnostic biopsy was doubled (17 to 34 days) and surgical consult to surgical date was doubled (12 vs 26.5 days). Eighty per cent (n = 27) of patients identified by OBSC presented with Stage I or less breast cancer vs 37% of all other patients. Seventeen per cent of patients seen at the regional cancer centre were less than 50 years of age and not eligible for the OBSC. Conclusions: The wait times reported are in keeping with the current experience in Ontario, Canada.[1] It is most likely that access to a breast-screening clinic allows self-selection of a more highly motivated population. This population of patients consistently presented with earlier stage and more curable disease. The challenge that remains is to increase the number of patients that access breast-screening clinics. Presently, only 13% of presenting patients seen at the regional cancer centre were identified by the OBSC. We are identifying barriers to the use of this very effective strategy. [1] Cancer Care Ontario. Ontario Wait Times Strategy. www.health.gov.on.ca. [Table: see text]

Download Full-text